99 cents of every dollar received funds cancer research.
Gateway for Cancer Research

Gateway for Cancer Research is a 501 (c)(3) nonprofit organization that funds innovative cancer research studies to make a difference in the lives of those living with cancer today. Gateway partners with forward-thinking researchers and provides much needed funding for bold, new phase I and phase II cancer clinical trials across the world.

Vision
To shape a world in which a cancer diagnosis is no longer feared.

Mission
To fund cancer research in new drug investigations, novel combination therapies, and complementary and alternative cancer treatments that will help cancer patients feel better, live longer or be cured TODAY!
Welcome Letter 5
Research Portfolio 6
Patient Story Spotlight: Richard Rogers 7
Researcher Spotlight: Dr. Robert Aiken 8
Patient Advocate: Kay Kays 9
Clinical Trials Funded in FY 2013 10
Cancer Researcher of the Year Award 12
Cures 2012 Gala 14
Independent Fundraisers 15
Team Demand 16
Strong Partnerships and Alliances 17
Financial Highlights 18
Generous Donors Listing 19
Board Members and Team 20

*This report covers research and fundraising from July 1, 2012 - June 30, 2013.
Dear Friends,

What an exciting time for patients, their caregivers, physicians, and researchers as Gateway brought forth new opportunities for cancer patients in need of better treatment solutions and cures. In addition to awarding funds to 13 new innovative cancer clinical trials, Gateway launched strategic initiatives that will expand our reach and enhance our capabilities to alter the way cancer is approached in research and treated at bedside.

In the past year we diversified and broadened our research portfolio to bring more treatment options to more patients in more regions across the world. New partnerships were formed with cancer research and cancer funding organizations overseas, paving the way for Gateway funded clinical trials in Europe. We also formed a Research Advisory Committee to address unmet patient needs and to determine how Gateway can best fill these gaps within early phase cancer research studies.

While our growth is remarkable, we have to remember what drives us each and every day: the patient. There is no greater cause and no greater calling for our organization than to make a difference in the lives of those affected by cancer every day!

Within this report you will learn about Gateway activities, achievements and research studies that your donations helped to make possible. I want to thank the cancer researchers who have partnered with us to bring forth better treatment solutions that impact lives TODAY! Most importantly, a round of applause is in order for the brave cancer patients who are fighting this mighty battle against cancer in every way possible. Your courage, strength and perseverance are admirable, and I thank you for sharing your stories of bravery and victory with us.

On behalf of the Board of Directors, Board of Scientific Counselors and Gateway team, thank you for partnering with us in this cause. Without your generosity and support, we would not be able to bring potentially lifesaving treatments to cancer patients who need them most… and that’s what truly matters most!

Together, we are making a difference in the fight against cancer…and your steadfast support is the reason for this difference.

Gratefully yours,

Richard J Stephenson
Chairman of the Board of Directors, Gateway for Cancer Research
One of Gateway’s guiding principles is to support cancer clinical trials that challenge the current research model through outside-the-box treatment innovations that may not otherwise be funded. While the traditional approach to cancer research has yielded notable successes over the years, Gateway is committed to seeing more advancement that gives greater attention to the needs of today’s cancer patients.

Gateway strives for a balanced research portfolio that encompasses a wide range of cancer treatment approaches with the aim to increase survival and quality of life. Our research grants portfolio consists of approximately 40% novel use/combination of existing drugs, 40% complementary and alternative medicine (CAM) therapies and 20% new therapy/drug discoveries.

Novel use/combination of existing drugs are studies that use drugs approved for other conditions in combination with cancer-targeted therapies to deliver a unique and potentially more-effective treatment plan. Complementary and alternative medicine treatments often use natural products, integrated wisdom medicine principles such as mind-body medicine, et al., to help boost the effectiveness of current therapies or minimize burdensome side effects. New drug and treatment discoveries are developed in an attempt to provide patients with safer, less toxic or more effective options for treating cancer.

The reason that 80% of our funding is dedicated to novel use and CAM research studies is because positive research results can benefit patients quickly due to a shorter FDA review and approval process. We deliberately limit the percentage of funds awarded to new drug investigations because the likelihood of studies closing or failing is comparatively higher. What’s more, the overall development phase can take years for a new drug to become an approved standard of care.

In Fiscal Year 2013, Gateway received 187 pre-grant applications, of which 22 were invited to submit a full grant application. At the recommendation of Gateway’s Board of Scientific Counselors, 13 were ultimately awarded with a research grant. In total, Gateway funded 26 clinical trials, including two international studies in Canada and Switzerland. More importantly, these research studies provided new treatment opportunities to 1,303 cancer patients, offering safer and more effective therapies that improve quality of life and restore hope for a healthier future.
FIGHTING MULTIPLE MYELOMA WITH THE IMMUNE SYSTEM

Blockade of PD-1 in Conjunction with the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Richard Rogers received news from doctors that he had a very aggressive form of multiple myeloma; his blood was 60 percent cancer. Before Richard began treatment, he learned about a Gateway funded clinical trial underway at Beth Israel Deaconess Medical Center in Boston. Dr. David Avigan was leading a promising treatment approach using a new vaccine and a patient’s immune system to more effectively target and destroy cancer cells.

After months of research and deliberation between Richard and his wife, he decided to participate in the clinical trial, which would first require a stem cell transplant. This was the first time Richard would be participating in a clinical trial, which made him slightly nervous and a bit overwhelmed. In an effort to stay strong, positive, and hopeful throughout the journey, Richard focused on a special goal, saying “My goal is to dance at my grand-daughters’ weddings.”

Dr. Avigan’s research study provides patients with an extra cancer-fighting antibody that amplifies the body’s immune response in its quest for a disease-free state. According to Dr. Avigan, cancer cells are able to grow in the body because they outsmart the immune system and create an environment where they cannot be recognized. The goal of Dr. Avigan’s study is to create a cancer vaccine that would reverse this process so the immune system can identify and attack the cancerous cells. The cancer vaccine is unique because it’s designed to teach the immune system to recognize the myeloma as foreign, attack the cancer cells and improve its work against cancer.

“We take new, bold clinical ideas and turn them into actual clinical realities. That is the focus of our work as well as Gateway’s.” – Dr. Avigan

After undergoing a stem cell transplant and receiving the cancer vaccine treatment from Dr. Avigan, Richard has been able to fight off cancer with even greater success. Today, Richard is cancer-free, and he plans to one day dance at his grand-daughters’ weddings.

– Richard Rogers
Clinical Trial Participant
Multiple Myeloma Survivor

Learn more about Richard’s story here: DemandCuresToday.org/Richard
New Drug Takes Aim at Brain Cancer

Phase I/II Trial of the IGF-1R Inhibitor, AXL 1717 for Treatment of Patients with Recurrent Malignant Astrocytoma

According to the National Cancer Institute, an estimated 23,000 individuals were diagnosed with brain cancer in 2013. Sadly, approximately 60 percent are expected to die from this aggressive disease. While treatment options are available by way of chemotherapy, radiation and surgery (to name just a few), there remains an apparent need for safer and more effective treatment solutions for today’s brain cancer patients.

At Rush University Medical Center in Chicago, Dr. Robert Aiken is exploring a new and potentially life-saving treatment option for patients with malignant brain tumors. With funding from the Gateway for Cancer Research, Dr. Aiken is leading the phase I/II clinical trial that treats patients with a new anticancer drug. The new drug is an insulin-like growth factor 1 receptor (IGF-1R) pathway inhibitor that prevents specific hormones from aiding in the growth of malignant tumor cells.

Dr. Aiken is the first researcher to use this specific drug to treat brain tumors. The preliminary data is very encouraging and the potential impact is even greater. This is the only drug aimed at regulating IGF-1R that is able to cross the blood-brain barrier, making this study a truly significant project that may provide less toxic therapies to patients who have few or no options. This treatment is much safer and may allow patients to live their lives to their fullest.

– Dr. Robert Aiken
Brain Cancer Researcher

Learn more about Dr. Aiken’s research here:
DemandCuresToday.org/Aiken
THE VOICE OF THE
Patient ADVOCATE

Kay Kays is not only a passionate advocate for today’s cancer patients, she is also a four-time cancer survivor who refused to give up her fight against the disease. “Everyone I talked to said ‘you’re going to die, you have pancreatic cancer,’ and I wanted more hope than that,” said Kays, who was diagnosed with cancer at age 44.

Kays first underwent surgery to remove the cancerous cells in her pancreas, but the disease returned five years later. Determined to beat this cancer, Kays researched her treatment options and found a procedure that would remove her pancreas and spleen without needing a transplant. It’s a surgical procedure that Kays says was made possible through advancements in cancer research.

Unfortunately the cancer returned yet again…two more times over the next four years. The cancer was on the move as tumors were found in her lymph nodes and lungs. Despite the news, Kays chose hope and perseverance rather than defeat and fear.

During the time of her recurrence, Kays was working in research as a patient advocate, and she was more knowledgeable about cancer diagnoses, new treatment innovations and outcomes than ever before. As an empowered patient, Kays became an active member of her own care team, sought second opinions, and researched emerging therapies in cancer research. “To me, it was knowing what was going on in research that helped me make some good health care choices,” said Kays, who has since remained in good health following successful treatments of chemotherapy and surgery.

Through all of her challenges and victories, Kays found strength and hope in cancer research. Now, as a thriving survivor, Kays dedicates her time to helping others affected by cancer by offering support and resources to patients just like her. Kays received special training as a patient advocate through the National Cancer Institute (NCI) and today serves on the Gateway Board of Scientific Counselors.

The BSC is comprised of various cancer research experts from leading institutions across the United States. Within the last two years, the BSC has expanded to include two patient advocates, one of which is Kay Kays. This multidisciplinary team is responsible for reviewing all research grant applications to ensure funded clinical trials are patient-centered, results-oriented and purposefully to help cancer patients TODAY!

As a BSC member, Kays offers valuable insights as both a survivor and trained patient advocate. She brings the voice of the patient to the forefront and raises critical questions that address treatment risks and benefits. For Kays, it’s important that each research study supports the physical and emotional needs of patients and their families during treatment and into survivorship.

Together, as a multidisciplinary team of cancer experts, Kays and the BSC members help researchers to design clinically-relevant research studies that consider the needs and well-being of enrolled patients.

– Kay Kays
Patient Advocate

Learn more about Kay’s story here:
DemandCuresToday.org/Kay
Advanced Malignancies

Drs. Siqing Fu and Razelle Kurzrock
MD Anderson Cancer Center
Surface-Controlled Water Soluble Curcumin in Patients with Advanced Malignancies

Dr. Joseph Pidala
Moffitt Cancer Center
Immune Suppressive Medications for Graft vs. Host Disease Following Stem Cell Transplants

Dr. Weili Sun
Children's Hospital Los Angeles
New Epigenetic Approaches to Leukemia Therapy for Children

Dr. Jeffery Wong
City of Hope
Targeted Radiation Therapy to Reduce Toxicity in Bone Marrow Transplantation

Dr. Clive Zent
Mayo Clinic
Early Treatment Intervention for Chronic Lymphocytic Leukemia (CLL)

Blood/Hematologic Malignancies

Dr. David Avigan
Beth Israel Deaconess Medical Center
Powerful New Tools for Battling Myeloma

Dr. Nelson Chao
Duke University
Microbiome and Stem Cell Transplantation: Home Care vs. Standard Hospital Care

Dr. Arthur Frankel
Scott and White Memorial Hospital
CD3 Immunotoxin Therapy of CTCL

Dr. Larry W. Kwak
MD Anderson Cancer Center
Personalized Cancer Therapy: Lymphoma and Myeloma

Bone/Tissue

Dr. Frank Balis
The Children's Hospital of Philadelphia
Prevention of Nephrotoxicity in Pediatric Osteosarcoma

Brain

Dr. Robert Aiken
Rush University Medical Center
IGF-1R Inhibitor for Patients with Recurrent Malignant Astrocytoma

Dr. Delphine Davis
University of Rochester Medical Center
Predicting Brain Tumor Recurrence

Dr. Pierre-Yves Dietrich
University Hospital Geneva
Peptide Cancer Vaccine for Glioblastoma

– Dr. Rebecca Aft
Breast Cancer Researcher
Breast
Dr. Rebecca Aft
Washington University (St. Louis)
Effects of Herceptin on Survival in Breast Cancer Patients

Dr. Lorenzo Cohen
MD Anderson Cancer Center
Comprehensive Integrative Oncology Clinical Trial

Dr. Leisha Emens
Johns Hopkins University
Innovative Vaccines to Combat Breast Cancer

Lung
Drs. Richard Pietras and Lee Goodglick
UCLA Jonsson Comprehensive Cancer Center
Combination Therapy for Advanced Non-Small Cell Lung Cancer

Dr. Dugald Seely
Canadian College of Naturopathic Medicine
Melatonin’s Clinical Effects on Immune and Inflammatory Systems

Melanoma/Skin
Dr. Patricia LoRusso, Karmanos Cancer Institute
Dr. Jeffrey Trent, TGen
Personalized Medicine for Patients with BRAF Wilde-Type Cancer

Cervical
Dr. Nagi Kumar
Moffitt Cancer Center
Ameliorating Symptoms of Cognitive Impairment in Women Treated with Chemotherapy for Breast Cancer

Prostate
Dr. Sanjay Gupta
Case Western Reserve University
Polyphenols in Prostate Cancer

Colon Colorectal
Dr. Misha Cohen
University of California, San Francisco
Treatment of Anal HSIL through Use of Chinese Herbal Topical Cream

Dr. Edward Lin
Fred Hutchinson Cancer Research
Center Two-Step ADAPT Therapy for Metastatic Colorectal Cancer

Dr. Kathleen Wesa
Memorial Sloan-Kettering Cancer Center
Vitamin D Levels in Colorectal Cancer

Sarcoma
Dr. Gary Schwartz
Memorial Sloan-Kettering Cancer Center
Combination Therapy for Patients with Advanced Metastatic Sarcoma

For the most up-to-date list of clinical trials funded by Gateway visit:
DemandCuresToday.org/cancer-research/current-trials
Gateway’s new Cancer Researcher of the Year Award celebrated cancer research heroes who work hard to discover better, safer and more effective cancer treatments that may help cancer patients feel better, live longer or be cured today. This inaugural recognition honored a Gateway funded researcher who has achieved measurable and significant excellence in the field of cancer research, in addition to positively impacting the lives of individuals living with cancer.

From among the 19 applications received, Gateway’s Award Committee narrowed down the finalists grouping to six highly decorated and achieved researchers. Each of the deserving finalists demonstrated truly remarkable contributions to patient care as well as an unprecedented level of advocacy, support and service for today’s cancer patients.

In the spirit of patient-centered care and collaboration, the final vote for the Award recipient rested upon Gateway’s network of supporters and the community at large. The level of engagement was tremendous, as more than 7,000 votes were received from across the country as well as abroad.

At Gateway’s Annual Meeting celebration, Dr. Pierre-Yves Dietrich of University Hospital Geneva in Switzerland was announced as the very first to be honored as Gateway’s Cancer Researcher of the Year. The energetic medical researcher has helped advance the field of cancer research with wide-reaching contributions spanning the laboratory, classroom and patient care setting.

“I am passionate about what I am doing and feel privileged to care for cancer patients. This award is an amazing source of motivation for both me and my team, of whom I share in this success for the outstanding quality of their work.”

Dr. Pierre-Yves Dietrich
Lung Cancer Researcher
AWARD RECIPIENT:  
PIERRE-YVES DIETRICH, MD, PhD

As a researcher, professor and oncologist, Dr. Dietrich is a shining example of an altruistic and passionate leader who pursues and applies knowledge in bold, new ways with a singular goal to help those afflicted by this deadly disease.

Fifteen years ago, Dr. Dietrich was one of the first to formulate and test a hypothesis that would leverage the immune system to help fight brain tumors. With conviction, passion and optimism for finding better cures with less side effects, Dr. Dietrich established the Laboratory of Tumor Immunology at the University Hospital Geneva in 1994. Dr. Dietrich and his research team yielded significant contributions to the field of cancer therapy with emphasis on brain tumor immunology. They gained insights on the mechanisms of effective anti-tumor immune responses in the brain, while also understanding how tumor cells seemingly evade attacks from the immune system.

A recent success for Dr. Dietrich was the identification of a series of cell surface molecules (glioma-associated antigens) that are present on tumor cells, but otherwise faint or absent on normal tissue. This discovery has paved the way for the development of immunotherapies (therapeutic vaccines, T cell therapy) in which the immune system can more accurately target tumor cells without compromising healthy brain tissue.

Gateway is currently funding Dr. Dietrich’s innovative clinical trial using a robust set of antigens to treat brain cancer patients.

Richard J Stephenson (at right) congratulates Dr. Dietrich at Gateway’s Annual Meeting.
CURES 2012 GALA

The Cures Gala is one of Chicago’s largest and brightest annual events where individuals who share a passion for cancer research came together for an elegant evening of dinner, dancing and cause. There were nearly 1,000 attendees, 140 corporate and private sponsors, and hundreds of individual donations. This star-studded evening raised almost $2.5 million for the Gateway for Cancer Research. Dina Bair, WGN-TV medical anchor and cancer survivor was the Gala’s mistress of ceremonies. Evening highlights included a performance by American Idol winner Lee DeWyze. Lee graced the stage with his personal and beautiful rendition of the song “Hallelujah,” along with one of his new songs titled “Fight.” Several members of the 1985 Chicago Bears Super Bowl team were also present for autographs.

Thank You

To Our Devoted Gala Committee Members!

- Tina Ballis
- Meghan Garofolo
- Bev Lynde
- Cindy Mayo
- Chris Pawlowski
- Pam Picchietti
- Paris Pyne Yesawich
- Dottie Rzeszutko
- Tami Vogel
CURES AHEAD GOLF INVITATIONAL

AHEAD and the Cancer Treatment Centers of America® (CTCA) Information Technology department joined forces to host the inaugural Cures Ahead Golf Invitational at The Glen Club in Glenview, Illinois. The golf event was conceived through a close working relationship between both organizations who share a passion for supporting the needs of today’s cancer patients. CTCA IT uses technology to improve the quality of patient care from first contact to completion of treatment, and AHEAD assists CTCA in this critical endeavor. Wanting to take their partnership to the next level by also supporting cancer research, AHEAD and CTCA’s IT team approached Gateway with the idea of an annual fundraising event at the highly acclaimed golf course.

The event was an instant success as nearly 100 golfers representing 28 companies participated in the inaugural golf invitational. Participants enjoyed a wonderful day of golf, raffle prizes and a closing dinner ceremony that reminded guests what the day was all about: cancer research. Among the many generous donors and sponsors were AHEAD and Cisco, who each donated $15,000 to Gateway. Between donations and sponsorships, $120,000 was raised to benefit Gateway.

SPARE TIME 4 A CURE

Spare Time 4 a Cure, which has been an annual fundraiser for the last 18 years, has become a highly anticipated event attended by dedicated members of the community, many of whom have been personally touched by cancer. More than 200 guests come together at a local bowling alley in Chicago for some friendly competition, to participate in a sports-themed raffle, to snack on pizza, and to enjoy time with friends and family. This annual fundraiser sells out each year and continues to raise about $10,000 for Gateway.

The dedication of event organizers Tim, Dave and Jim is inspiring and showcases what’s possible when our supporters apply hard work and passion toward a good cause. Spare Time 4 a Cure has become more than a typical fundraiser and has grown into a family-like gathering that brings together enthusiastic individuals who share a heart for finding cures and providing hope for today’s cancer patients.
Team Demand is a national charity athlete program uniting cause and community where individuals rally together with two goals in mind – to lead an active lifestyle and to raise funds for bold, new cancer research. Athletes of all levels have represented Team Demand in competitive and family-fun events that include local run/walk, cycling, golfing, and mudathalon competitions – really, any sporting activity. Team Demand members and supporters are spreading the urgent message that better, safer and more effective cancer treatments are needed for today’s cancer patients.

Team Demand participated in 13 races this year, which included the Chicago Half Marathon, Chicagoland Spring Marathon and Half Marathon, and the Georgia Publix Marathon and Half Marathon. Gateway partnered with an endurance race company and secured charity beneficiary status for two races in Illinois. This partnership raised additional visibility and money for the organization. During FY 2013, Team Demand charity athletes raised more than $31,000.

Are you interested in running, walking or biking to help raise money for cancer research? Learn more and form your very own team for any event by visiting: DemandCuresToday.org/TeamDemand

@DemandCures /TeamDemandCures
Mission Partner: Clune Construction Company

Gateway received a truly generous multi-year donation that will help to continue funding innovative cancer clinical trials across the world that aim to help cancer patients everywhere feel better, live longer or be cured TODAY! The unprecedented $1 million contribution came from philanthropic corporate executive, Michael T. Clune, on behalf of his private general construction company, Clune Construction.

“We are humbled to receive this generous gift and thrilled that Mr. Clune and the entire Clune Construction team have emphatically partnered with us in our quest to one day see a world in which a cancer diagnoses is no longer feared,” said Karen Kay, Director of Development at the Gateway for Cancer Research.

Kay adds that a donation of this magnitude has the potential to impact thousands of lives, and “it gives us greater hope that better cancer treatments and even a cancer cure can be seen in this generation.”

Mr. Clune was inspired to become a leading mission partner because of Gateway’s passion and unique approach to funding cancer research. “Late last year I had the opportunity to become involved with the Gateway for Cancer Research and was highly impressed with the organization,” said Clune. “I was deeply moved by their commitment to the cause of cancer research, and with their rigorous process for administering funds. Nearly 99 cents of every dollar donated to Gateway goes directly to cancer research, which is an exceptional percentage relative to other nonprofits.”

Charity Partner: Cancer Sucks

Cancer Sucks is a nonprofit organization that raises funds in the most creative and fun way to support organizations, such as Gateway, that facilitate cancer research studies. A $70,000 donation came from proceeds raised at the eighth annual Cancer Sucks concert in Tulsa, as well as the 2012 Shiprocked Cruise in which Cancer Sucks was the benefiting charity of choice for the event’s lucrative auction of music memorabilia.

“There’s great synergy between these two organizations, and our relationship with Cancer Sucks continues to grow,” said Karen Kay. “We are both committed to spreading the urgent message that cancer treatment solutions are needed now, because too many patients are left waiting for answers.”

For more than ten years, Cancer Sucks has been a vocal supporter of Gateway’s mission to fund innovative, conventional and alternative cancer treatment therapies. This gift is the largest single donation made by the organization to Gateway, and the dynamic relationship between these two nonprofits is expected to grow in years to come.
**FINANCIAL HIGHLIGHTS**

**Year Ended June 30, 2013**

### FUNDRAISING REVENUE

- Contributions: $829,724
- Special Events: $2,432,314

### RESEARCH GRANTS

- Awarded Grant Funds: $1,788,480

### ASSETS

- Cash and Cash Equivalents: $7,976,449
- Pledges and other receivables: $310,944
- Certificates of Deposit: $1,616,118
- Interests in Limited Partnerships: $8,350
  
  **Total Assets**: $9,911,861

### LIABILITIES AND NET ASSETS

- Accrued Grants: $3,768,961
- Accrued Expenses: $292
-Deferred Revenue: $45,520
- Net Assets: $6,097,088

**Total Net Assets and Liabilities**: $9,911,861

*Thanks to generous underwriting by Cancer Treatment Centers of America for Gateway’s administrative expenses, which includes employee compensation, 99% of all contributions received directly fund researchers who are conducting phase I and phase II cancer clinical trials.*

*Form 990 available upon request.*
TO OUR DONORS . . .

Your unwavering commitment and generosity is humbling. Your support and resources equip us to move forward with unhindered boldness in our shared cause to find and fund better cancer treatments.
OUR GENEROUS DONORS: FY2013

PLATINUM DONORS
($100,000 and above)
AmerisourceBergen
The Richard Templer Family

GOLD DONORS
($50,000 - $99,999)
The Bonner Family
CancerSucks, Inc.
Cancer Treatment Centers of America
Rising Tide
Mr. Richard J Stephenson and Dr. Stacie Macari

SILVER DONORS
($25,000 - $49,999)
AHEAD
Bank of America Foundation
Blue Cross Blue Shield of Illinois
Cancer Nutrition Centers of America
CliftonLarsonAllen, LLP
Mr. and Mrs. Bryan Cressey
CTCA at Eastern Regional Medical Center
CTCA at Midwestern Regional Medical Center
CTCA at Southeastern Regional Medical Center
CTCA at Southwestern Regional Medical Center
CTCA at Western Regional Medical Center
Mr. and Mrs. Timothy J. Danis
Illinois Tool Works
Insight Enterprises, Inc.
Integrated Media Solutions, LLC
International Capital and Management Company
J.B. and M.K. Pritzker Family Foundation
Kailo
Katten Muchin & Roseman
Mr. and Mrs. Darren P. Keller
Litchfield Advisors Incorporated
Magellan Corporation
Northern Illinois Flight Center, Inc.
PNC
Stellar Insurance
Ms. Annie Stephenson and Mr. William Hostetler
Dr. and Mrs. Christopher Stephenson
Shawn and Morgan Stepehson
Ms. Shelby Stephenson
Vital Support Systems
Walgreens

BRONZE DONORS
($10,000 - $24,999)
Allstate Insurance Company
American Heritage Life Insurance Company
The Bill Bass Foundation
Burwood Group
Carettech Solutions
Mr. Roger Cary and Mrs. Honor Guthrie
Choose Hope, Inc.
CIGNA
ComEd
CTCA at Seattle Cancer Treatment and Wellness Center
Dewberry Architects, Inc.
The Edgewater Funds
EMC Corporation
Mr. and Mrs. Larry Ewing
Fred & Jean Allegretti Foundation
FreedomWorks
Grosvenor Holdings, LLC
Harbour Group Investments
Mr. and Mrs. Christopher Hargan
Havas Edge
H.I.G. Capital
Hollister Incorporated
Holuvi Enterprises LLC
Mr. Brian Hubbell
Mr. & Mrs. Paul Kelly
Mr. and Mrs. Thomas E. Lechowicz
The Honorable Stephen Manrose and Mrs. Janet Horn
Mr. and Mrs. Robert Mayo
Ms. Anne Meisner
Motorola Solutions, Inc.
New Resources Consulting LLC
Mr. and Mrs. Thomas Nolan
The Northern Trust Corporation
Numerof & Associates, Inc.
Paulson & Company
The Private Bank and Trust Co.
The Riverside Company
S&C Foundation
Stradley, Ronon, Stevens & Young, LLP
Sunquest Information Systems
Talent +
Van Cleef and Arpels
VMware
Wells Fargo
Dr. and Mrs. Peter C. Yesawich

**CIRCLE OF HOPE**
($1,000 - $9,999)
Mr. Tim Abeyta
Mr. and Mrs. Peter Abuls
Ms. Robin Adams
Admiral Heating and Ventilating, Inc.,
All Community Events
Ms. Marie Allen
Mr. Mike Allietta
Allscripts
Mrs. Lindsay Ambrose
American Legion Post 5
Amgen
Mr. Donald Ami and Mrs. Kristine K. Sudrovec Ami
Mr. Arthur Anderson
Aon Hewitt
Arlington Resources
Associated Bank
Attadale Partners, LLC
Mr. and Mrs. Algis Augustine
Avanade
Mr. and Mrs. Dennis Baker
Baker Commodities, Inc.
Dr. Maan Barhoum
Mr. and Mrs. Charles Bartels
Batson-Cook Company
Baxter International
Ms. Lori Beard
Mrs. Holly Behanna
Mr. and Mrs. Karl Berens
Mr. and Mrs. Sam Bieilig
Drs. Timothy and Shauna Birdsall
Mr. and Mrs. Anthony Blood
Ms. Angela Boettcher
Mr. Glenn Boland
Mr. & Mrs. John Bolduc
Mr. and Mrs. Pierre Bongard

Dr. Tammy Born
Dr. and Mrs. Donald Braun
Mrs. Alora Brock
Mrs. Mary Brooks
Mr. Michael Brooks
Mr. Harry Buchman
Ms. Lisa Buckner
Mr. David Burland
C.A. Fortune and Company
Mr. Brian Caliendo
Ms. Debbie Callahan
Mr. Matt Candle
Carson Private Capital
Mr. and Mrs. Michael V. Capozzi
Mr. and Mrs. Victor Caricato
Mr. and Mrs. Paulie Carus
CDW Computer Centers
Dr. and Mrs. Sung K. Chang
Dr. and Mrs. Jeffrey T. Choh
Cisco Systems
Mr. Jay Colfer
Mr. Ross Conner
Ms. Maureen Conroy
Mr. and Mrs. Dean Conterato
Mr. & Mrs. John G. Conway
Mr. Michael Coulter-Smith
Crain’s Chicago Business
Ms. Pamela Crilley
Ms. Sue Crothers
CTC Trading Group, LLC
Mr. Robert Cudworth
Ms. Zalenda Cyrille
Ms. Nancy Dall
Dr. and Mrs. George Daneker
Mr. Paul Darby
Mr. and Mrs. Scott Davis
Mr. and Mrs. Chuck Day
Mr. and Mrs. John L. Dearlove
Mr. Herbert L. De Barba, Jr.
Ms. Irie Dennis
Mr. and Mrs. Walter Denny
Ms. Helen Denslow
Mr. and Mrs. Wayne Dixon
Mr. and Mrs. Christopher Downs
Mr. Chris Dray
Drink
The DSF Group
Dubois Enterprises, Inc.
The Duchossois Group, Inc
Mr. Harold J. Eason
Eckes Family
Dr. and Mrs. Bernard V. Eden
Mr. Jon Egan
Mr. and Mrs. James Eller
Emerson Ecologics
Ms. Deete Emon
Entertainment Industry Foundation
Executive Leverage, Incorporated
FirstMark Capital
Mr. and Mrs. Allen Fleming
Dr. and Mrs. James Flynn
Ms. Alicia Freed
Ms. Alexis Goldstone
Mr. and Mrs. Richard Galgan
Dr. Bruce Gershenson
Mr. and Mrs. Jeff Geuder
Give with Liberty
Mr. and Mrs. Ronald C. Glig
Mr. Anthony Gobereochin
Gold Pan Bar
Mr. John Goodchild
Mr. John Grady
Mr. Richard Griffith
Mr. and Mrs. James Grogan
Ms. Leslie A. Haas
Mr. Brian Hahn
Mr. Andrew Hammar
Mr. and Mrs. Chris Hamrick
Mr. Greg Harrell-Edge
Mr. and Mrs. Charles Harris
Mr. and Mrs. Barry A. Hartstein
Mr. Scott Hauser
Ms. Dana Haynie
Mr. David Hedges
Ms. Charlotte Hendrickson
Mr. and Mrs. Brian G. Hirt
Inhalation, Inc.
Interior Construction Group
Ms. Patti J. Jarvis
Mr. and Mrs. Scott Johnson
Mr. and Mrs. Scott E. Jones
Ms. Katie Kelly
Mr. and Mrs. David C. Kent
Dr. and Mrs. Jay Kent-Ferraro
Mr. Dennis E. Kepler
Mr. and Mrs. Kim Kidd
Mr. Kieknens
Mr. Pat Kinsella
Mr. Eiko Klimant
Mr. Stewart Kohl
Mr. and Mrs. Jeff Konz
KPMG LLP
Mr. Steven L. Kroll and Mrs. Jenny R. Patterson
Ms. Tina Krueger

Mr. Robert Kulka
Ms. Carolyn A. Lammersfeld
Lauzon & Euler, LLP
Dr. Pablo Lavagnini
Mr. Adam R. Lefton and Ms. Margaret Skupa
Mr. Scott Leisher
Dr. and Mrs. Robert Levin
Mr. and Mrs. Jonathan Lewis
Liberty Creative Solutions
Lightspan Digital, LLC
Dr. and Mrs. Christopher Lis
Mr. Alex Loucks
Mr. Michael Low
Mr. and Mrs. Bruce S. Lubin
Mr. Jason Lucas
Mr. and Mrs. Dennis Lynde
Mr. and Mrs. Stephen L. Mackin
Mr. and Mrs. Eric Magnussen
Mr. and Mrs. Ryan Maher
Mr. and Mrs. James Mansk
Marsh U.S.
Mr. and Mrs. Joseph Marshall
Mr. and Mrs. Steven C. McFadden
Mr. and Mrs. Matthew A. McGuire
Mr. and Mrs. John McNeil
MedAssets, Inc.
Medproperties, LLC
Meisrow Financial
Dr. and Mrs. Alfonso V. Melljor
Mr. Richard Menna
Mr. Anthony Minor
Ms. Victoria Moncello
Monroe Capital
Mr. and Mrs. Tim Mosier
Mr. Anthony Mullizio
Ms. Nancy Mullally
Mr. and Mrs. Michael Mullen
Mr. and Mrs. Michael Mullins
Mr. and Mrs. Rod A. Murray
Mr. George Mutz
My Sister Mary Foundation
Nansen Inc
Dr. Rakhsanda Neelam and Rehan Aslam
Mr. Steve Netzley
New Trend Electronics
Mr. & Mrs. Joe Nicholson
Mr. David Ninow
Ms. Nora Noell
Mr. and Mrs. Mitch Northcutt
Mr. & Mrs. Tom Oberdorf
Dr. Adaora Oguefe
Oklahoma Association of Naturopathic Physicians
Dr. Clarence G. Oliver, Jr., Ed.D.
Dr. James Olson and Ms. Alice Byrne
Mr. and Mrs. William C. Olson
OneHope Foundation
Onyx Worldwide AG
Mr. and Mrs. Donald M. Orrick
Ms. Kristie Paskvan
Dr. and Mrs. Kamal Patel
Mr. David Patrick
Mrs. Connie Payton
Ms. Aaron Pelletier
Mr. and Mrs. Phillip Picchietti
PlasmaNet, Inc.
Ms. Michelle Pluskota
Mr. and Mrs. Arthur P. Poirier
Mr. and Mrs. Thomas Pradd
Prairie Capital
Preferred Medical Claims Solutions
Dr. Katherine L. Puckett
Mr. and Mrs. Leo Radvinsky
Mr. and Mrs. Douglas Rath
Mr. and Mrs. Bruce Rauner
Dr. Stephen P. Ray
Drs. Istvan Redei and Elizabeth Ann Fajardo
Mr. William Reed
Ms. Erin Reef
Mr. Sean Reynolds
Mr. and Mrs. Walt Reichel
Mr. and Mrs. Charles Ribbe
Ms. Kathryn Rice
Mr. and Mrs. Richard A. Riley
Rise Above Group
Mr. and Mrs. Edwin Roberson
Mr. Louis Roitblat
Dr. and Mrs. James Rosenberg
Mr. Andrew Roth
Mr. John W. Rowe
Mr. Stephen L. Rusinko
Mr. Jeffrey Ryan
Mr. and Mrs. Ron Sachs
Dr. and Mrs. Ranulfo Sanchez
Mr. and Mrs. Eric Sato
Scheck Oil
Ms. Elena Schroeder
Mr. and Mrs. Horst Schulze
Mr. Thomas Schwartz
Mr. & Mrs. Samuel Scott, III
Mr. Howard Seedof and Ms. Cheryl Marchese
Mr. and Mrs. Benjamin Seib
Mr. Cary Serif
Mr. Nathaniel Sher
Signature Technology Group

Mr. Noah Silvers
Mr. Alan Silverstein
Simple Truth Communications Partners
Dr. and Mrs. Pakorn Sirijintakarn
Mr. and Mrs. Andy Smith
Maryl Smith Agencies
Mrs. Maryl Smith
Mr. Kevin Snyder
Solis Capital Partners, LLC
Mr. Michael A. Spadaccini
Ms. Vera Stamenkovich
Mr. & Mrs. Harrison Steans
Dr. and Mrs. Steven Standiford
Dr. and Mrs. Edgar D. Staren
Mr. and Mrs. John Steiner
Dr. & Mrs. Paul Steinwald
St. Paul M.B. Church of Pleasant Hill
Suburban Windy City USBC
Ms. Mary Sukel
Mr. and Mrs. Matt Sukel
Sunquest
Surgical Information Systems, LLC
Mr. and Mrs. David Szolnicki
Mr. Tom Talbot
Mr. and Mrs. Greg Tait
Dr. Bradford A. Tan and Dr. Ailyn Tan
Miss Cecilia Taylor
Team National Products, Inc.
Mr. Harlan R. Teller
Thomas R. Duensing & Associates, LTD.
Mr. Herman Tiemens
Mr. Michael Toolis
Mr. and Mrs. Charles M. Towns
Dr. and Mrs. E. Steven Townsend
Mr. and Mrs. Charles Trammell
Mr. Jeffrey Trent
Mr. and Mrs. Bernard R. Tresnowski
Ms. Katherine Tron
Tunstall / American Medical Alert Corporation
Mr. George Turner and Ms. Andrea Van Gelder
Ms. Terri B. Ucci
Mr. and Mrs. Drew Unger
Mr. Dennis Upah
Mr. Barry Uphoff
US Raceworks LLC
Mr. and Mrs. Jeff Van Horn
Mr. Zacharias Varughese
Drs. Pankaj Vashi
Vedder Price PC
Mr. and Mrs. Jonathan Vegosen
Mr. and Mrs. Jim Vogel
Mr. Michael Vrchota
Mr. Scott A. Walker  
Walsh Construction Company  
Ms. Kathleen Walsh  
Mr. and Mrs. Tony Whelan  
Mr. & Mrs. Greg White  
Mr. Michael White  
Ms. Pamela White  
Mr. Scott Whiteford  
Mr. and Mrs. Ray Wiest  
Mr. and Mrs. Cornel Williams  
Mr. and Mrs. Alan Wilson  
Windstream Corporation  
Mr. and Mrs. David B. Winn  
Winston & Strawn LLP  
Dr. Sylvia Xi-Moy  
Ms. Cindy Yates  
Dr. and Mrs. Kenny Yoo  
Ms. Kelly Young  
Mr. Wendelin Zellmayer  
Mr. and Mrs. Joseph L. Zook  

CIRCLE OF FRIENDS  
($500 - $999)  
Mr. and Mrs. Brian Acord  
Mr. and Mrs. Sari M. Alamuddin  
AT&T  
Mr. and Mrs. Michael Austin  
Mr. Ravi Bahirwani  
Mr. Chris Baier  
Ms. Gloria V. Barnes  
Mr. Bhaskaran & Ms. Parmeswaran  
Ms. Carolyn Bilson  
Bluestein & Associates  
Mr. Matt Braun  
Mrs. Shannon Bristow  
Ms. Elvina Bukowski  
Ms. Bryana Bunte  
Mr. & Mrs. Ray Butera  
Mr. Mr. Richard Caffrey  
Ms. Elaine Canning  
Capital Trading Group  
Mr. Don Capriglione and Ms. Chris Cullinan  
Ms. Michelle Castle  
Mrs. Fong Chen  
Mrs. Carol Christian  
Mr. Phil Chrysler  
Crown Castle USA Inc.  
Dr. John R. Delbridge  
Mr. Philippe Demilde  
Ms. Johanna Dillon  
Mr. Mark Drozd  
Mr. Scott Duval  

EDR Industries  
Ms. Elke Elliott  
Mr. Scott F. Elphinstone MBA,CA,CFA  
Mrs. Anne Eng  
Mr. & Mrs. Thomas Erdelac  
Mr. and Mrs. Stephen Erskine  
Mr. Arthur E. Fossland  
Mr. Paul Furlinger  
Mr. David K. Gierhart  
Mr. and Mrs. Scott Gilbertson  
Ms. Paula Godwin  
Mr. and Mrs. Jayme Goliash  
Ms. Elaine Granado  
Mr. & Mrs. Michael Gresavage  
Ms. Mary A. Harris  
Mr. Mark Havlic  
Mr. and Mrs. Craig Holick  
Mr. Clinton Howell  
Mr. Adrian Huber  
Indianapolis Colts  
Mr. Kenrick Isaac  
Mr. and Mrs. Roderick C. Isham  
J. Crew  
Ms. Caida Jorat  
Miss Heather Jordan  
JHS Natural Products  
Jackie L. Kapaun  
Ms. Julia Kaplan  
Mr. and Mrs. Kevin Kearns  
Ms. Rhonda Kokot  
Ms. Kimberly B. Krause  
Ms. Amy Littleton  
Ms. Shannon Loewy  
Lorraine Spada School of Dance  
Ms. Thersea Luty  
Mr. Brian Lynch  
Mr. Yves Maag  
Mr. and Mrs. Patrick Maley  
Mr. Todd Mejidzadeh  
Dr. Maurie Markman  
Mr. Jon Madorsky  
Ms. Susan Marshall  
Mr. Richard Mascarenhas  
Mr. Thomas Mazza  
Mr. Kerry McCan  
Ms. Laura McDowell  
Ms. Carol McGuire  
Mr. David McKeehan  
Mr. Frank McLaughlin  
Merchant Services  
Microlight Corporation of America  
Mr. Paul Miller
Millward Brown
Mr. Frank Misureli
Ms. Devree Molnar-Kovoor
Moyer Repair Service
Mudathlon, LLC
Mr. & Mrs. Walter Mullaney
Mr. Aaron Nack
New York City Transit Authority
Ms. Erin Ohlms
Ms. Mary Parello
Mr. Raju Patel
Mr. Timothy Rafter
Dr. & Mrs. Raed Rahman
Dr. Russell Reisner
Mrs. Barbara E. Richardson
Mr. Stuart Richter
Rooms To Go
Mr. Jonathan Sarvis
Ms. Anna Saunders-Nero
Sawyier & Williams, LLP
Ms. Sharon Schembri

Mr. Alfred Schiedegger
Ms. Anne Seneca
Mr. Brian Shannon
Much Shelist
Mr. and Mrs. Ron Shotts
Ms. Jennifer Smith
Mr. Marc Sparber
Mr. Michael Stevens
Mr. and Mr. James V. Stibgen
Mr. and Mrs. Robert Stockley
Mr. Allen Sweet
Mr. and Mrs. Paul Templer
Ms. Alice Jean Tiemens
Mr. Phillip Tortorich
Mr. Lee Tosi
Mr. and Mrs. Charles Towns
Mr. Mike Turner
Ms. Lori VanderBoegh
Ms. Jeanette Wheeler
Ms. Katrina Williams
Dr. & Mrs. Leon Yoder

THANK YOU

These donations represent cash gifts received from
July 1, 2012 – June 30, 2013. We make every attempt to include
and highlight the generosity of our donors. If you name isn’t included on
this list and you made a donation of $500 or above please let us know.
BOARD OF DIRECTORS

Chairman
Richard J Stephenson
Cancer Treatment Centers of America

Vice Chairman
Bruce Lubin
The Private Bank & Trust Co.

Vice President
Dottie Rzeszutko
CA Fortune

Treasurer
Michael T. Mullins
Winston & Strawn, LLP

Secretary
Rod Murray
Associated Bank

Directors
Michael Clune
Clune Construction Co.

Wayne Dixon
H.S. Crocker Co., Inc.

Tom Duensing
Thomas R. Duensing and Assoc.

Susan Fleming
Catamaran

Rhonda Kokot
Simple Truth

Heather Kane
United Healthcare

Robert Mayo
Cancer Treatment Centers of America

Edwin Roberson
Raphael Biotech, Inc.

Mary Lou Smith, JD
Research Advocacy Network

BOARD OF SCIENTIFIC COUNSELORS

Nelson Chao, MD
Duke University Medical Center

Timothy Fleming, PhD
Washington University School of Medicine

Robert Fine, MD
Columbia University

Judy Fulop, ND
Northwestern Integrative Medicine

Roy Andrew Jensen, MD
University of Kansas Cancer Center

Kay Kays
Patient Advocate and Co-founder Tissue Donor Awareness Program and Pancreatic Cancer Network

David Lacewell
Patient Advocate and Head of New Business Insights Oncology at Abbott Laboratories
Co-founder Max Lacewell Foundation

Jeannine McCune, Pharm.D
University of Washington Medical Center

Ronald Morton, MD
American Medical Systems

Kourosh Owzar, PhD
Duke University Medical Center

Joseph Pizzorno, ND
Bastyr University

RESEARCH ADVISORY COMMITTEE

Gary Deng, MD, PhD
Memorial Sloan-Kettering Cancer Center

Razelle Kurzrock, MD
UC San Diego Moores Cancer Center

Robert Mayo
Cancer Treatment Centers of America

Eveline Mumenthaler
Rising Tide Foundation

Mary Lou Smith, JD
Research Advocacy Network

*Listings current as of March 1, 2014
CHAIRMAN’S COUNCIL
Monica Brubaker
New Life Printing & Services

Julie Capozzi
Allstate Insurance Company

Paul Darby
Ted Moudis Associates

Tom Duensing
Thomas R. Duensing & Assoc.

Amy Egelson
Plante Moran

Dan Garms
The Garms Group, Inc

Mike Graveline
PNC Capital Advisors

Dan Greenman
Daniel Greenman & Co., P.C.

Christopher Hubbard
Pensare Group

Anne Majewski, MD
McHenry County Coroner

Dora Maya, Ph.D.
Arden Shore

Julie McDonald
Accelerated Rehab

Robert Payton
Arden Shore

Dottie Rzeszutko
CA Fortune

Maryl Smith
Maryl Smith Agencies

ASSOCIATES BOARD
Chair
Jaime Haak
Evolution 1

Communications Chair
Paul Elsberg
Exelon Corporation

Event Committee Co-Chair
Whitney Anderson
Edelman

Event Committee Co-Chair
TJ Gilboy
Pearre & Associates

Membership Chair
Christi Mayo
Cancer Treatment Centers of America

Treasurer
Diana Bell
FTI Consulting

Secretary
Jessie Hierstein
Dow Chemical

Justin Alden
Medical Search Technologies

Teresa Hall Bartels
President

Carol Christian
e-Marketing Manager

Wendy Lynn Duffer
Marketing Specialist

Jeremy Garber
Development Specialist

Kathy Gehrig
Assistant

Karen Kay
Director of Development

Ashele Landis
Marketing Specialist

Domarina Oshana, PhD
Director of Research and Grants

Delora Senft
Development Specialist

Adam Zuckerman
Marketing Manager

GATEWAY TEAM MEMBERS

Adriana Rosales
Research Grant Specialist

*Listings current as of March 1, 2014
DemandCuresToday.org

There are many ways you can join us to Demand Cures Today so more cancer patients can be survivors. Join the conversation on Facebook and Twitter, submit a story to the Cancer Canvas, or Fund-A-Day in honor of a loved one or friend.